A U.S. jury awarded Nektar Therapeutics $90 million in damages in its dispute with Eli Lilly over a fractured licensing deal covering the autoimmune disease drug rezpegaldesleukin (rezpeg). The verdict found Lilly breached the implied covenant of good faith and fair dealing, though the payout was far below the amount Nektar sought. The decision follows a 2023 complaint filed by Nektar, with the case centered on development and collaboration obligations tied to the investigational Treg-stimulator. The ruling underscores how contract terms and execution can materially alter cash flow and timelines for platform- and cytokine-based programs. For the industry, the case is another signal that biotech partnerships remain legally and strategically high-stakes, even after scientific collaboration begins. It also adds to the arbitration-and-litigation backdrop shaping how licensors structure future co-development deals.